Alpha-glucosidase Inhibitors

Alpha-glucosidase Inhibitors: Clinically Promising Candidates for Anti-diabetic Drug Discovery presents information that researchers can use to address a whole host of promising leads for the development of novel, oral, anti-diabetic drugs with improved efficacy and fewer side effects. Beginning with a discussion of the huge potential of a -glucosidase inhibitor leads and adaptations, and highlighting their importance within the field of anti-diabetic drug discovery, the book provides chemical structures, detailed background information and in vivo and in vitro biological activity data, and more economical adaptations of these structures. Drawing on the author's expert research in the field, this book highlights promising leads for development and helps researchers select the most appropriate inhibitors for their own work. It is a useful tool not only for anti-diabetic drug development researchers, but also for those whose research may be enhanced by an understanding of a -glucosidase inhibitor chemistry and activity. - Identifies and presents promising a-glucosidase inhibitors of natural and synthetic origin that belong to a variety of chemical classes - Compiles chemical structures and detailed in vivo and in vitro biological activity data that will help researchers select inhibitors for further work - Discusses promising avenues and potential challenges in the development of new a-glucosidase inhibitors based on their activity data

Usman Ghani is Assistant Professor of Biochemistry at King Saud University (KSU), Saudi Arabia. After gaining experience as a Chemist and Researcher in Pakistan, he completed his PhD at the University of Alberta, Canada, and took up a Postdoctoral Fellowship there before moving to KSU in 2005. He has been awarded numerous research grants and has published 23 papers to date.Prof Ghani's current research involves screening and identification of clinically important enzyme inhibitors and studies on their mechanism of inhibition. His team has identified a number of synthetic and natural inhibitors of tyrosinase and alpha-glucosidase enzymes that may become potential candidates for development into drugs for the treatment of hyperpigmentation and diabetes respectively.